This article is part of the network’s archive of useful research information. This article is closed to new comments due to inactivity. We welcome new content which can be done by submitting an article for review or take part in discussions in an open topic or submit a blog post to take your discussions online.
In a press release on 20th February 2019, Inovio Pharmaceuticals, Inc. (NASDAQ: INO) in collaboration with The Wistar Institute and the University of Pennsylvania announced the launch of a trial of a DNA-encoded monoclonal antibody (dMAb) technology, which will evaluate its ability to prevent or treat Zika virus infection (ZIKV).
This is being funded by the Bill & Melinda Gates Foundation; for more information, please follow this link; https://www.prnewswire.com/news-releases/inovio-announces-first-subject-dosed-with-its-dna-encoded-monoclonal-antibody-dmab-in-first-ever-human-trial-300798498.html